{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:27:47Z","timestamp":1768001267211,"version":"3.49.0"},"reference-count":50,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mayo CCaTS","award":["UL1TR000135"],"award-info":[{"award-number":["UL1TR000135"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Treatment with abiraterone acetate and prednisone (AA\/P) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients. We evaluated the genetic variation in CYP17A1 as predictive of response to AA\/P. A prospective collection of germline DNA prior to AA\/P initiation and follow-up of a mCRPC cohort was performed. Five common single-nucleotide polymorphisms (SNPs) in CYP17A1 identified using a haplotype-based tagging algorithm were genotyped. Clinical outcomes included biochemical response and time to biochemical progression on AA\/P. Logistic regression was used to assess the association between tag SNPs and biochemical response. Proportional hazards regression was used to assess the association between tag SNPs and time to biochemical progression. Odds or hazard ratio per minor allele were estimated and p-values below 0.05 were considered statistically significant. Germline DNA was successfully genotyped for four tag SNPs in 87 patients. The median age was 73 years (54\u201390); the median prostate-specific antigen was 66 ng\/dL (0.1\u201399.9). A single SNP, rs2486758, was associated with lower odds of experiencing a biochemical response (Odds ratio 0.22, 95% confidence interval 0.07\u20130.63, p = 0.005) and a shorter time to biochemical progression (Hazard ratio 2.23, 95% confidence interval 1.39\u20133.56, p &lt; 0.001). This tag SNP located in the promoter region of CYP17A1 will need further validation as a predictive biomarker for AA\/P therapy.<\/jats:p>","DOI":"10.3390\/ijms17071097","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T09:47:19Z","timestamp":1468230439000},"page":"1097","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hillman","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhea","family":"Kohli","sequence":"additional","affiliation":[{"name":"Mayo High School, 1420 11th Avenue SE, Rochester, MN 55904, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanvi","family":"Kohli","sequence":"additional","affiliation":[{"name":"Mayo High School, 1420 11th Avenue SE, Rochester, MN 55904, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Lee","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology Department, University of Minnesota, 515 Delaware St. SE, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Kohli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00000658-194206000-00030","article-title":"Effect of orchiectomy and irradiation on cancer of the prostate","volume":"115","author":"Huggins","year":"1942","journal-title":"Ann. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jama.1946.02870240008003","article-title":"Prostatic cancer treated by orchiectomy; the five year results","volume":"131","author":"Huggins","year":"1946","journal-title":"J. Am. Med. Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941","volume":"168","author":"Huggins","year":"2002","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000019546","article-title":"Maximal androgen blockade: Final analysis of eortc phase iii trial 30853. Eortc genito-urinary tract cancer cooperative group and the eortc data center","volume":"33","author":"Denis","year":"1998","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Prostate Cancer Trialists\u2019 Collaborative Group (2000). Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet, 355, 1491\u20131498.","DOI":"10.1016\/S0140-6736(00)02163-2"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"Logothetis","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature10743","article-title":"Structures of cytochrome p450 17a1 with prostate cancer drugs abiraterone and tok-001","volume":"482","author":"DeVore","year":"2012","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng.361","article-title":"Genome-wide association study identifies eight loci associated with blood pressure","volume":"41","author":"Johnson","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ng.384","article-title":"Genome-wide association study of blood pressure and hypertension","volume":"41","author":"Levy","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature10405","article-title":"Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk","volume":"478","author":"Ehret","year":"2011","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","article-title":"Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1158\/1055-9965.EPI-09-0076","article-title":"Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer","volume":"18","author":"Beuten","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1055-9965.EPI-07-0589","article-title":"CYP17 genetic variation and risk of breast and prostate cancer from the national cancer institute breast and prostate cancer cohort consortium (BPC3)","volume":"16","author":"Setiawan","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11077","DOI":"10.1158\/0008-5472.CAN-06-3024","article-title":"Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome p450, and steroid-5-\u03b1-reductase type 2 is important for prostate cancer development","volume":"66","author":"Wiklund","year":"2006","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1158\/1078-0432.CCR-07-0669","article-title":"Inherited variation in hormone-regulating genes and prostate cancer survival","volume":"13","author":"Adami","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/pros.21332","article-title":"CYP17 gene polymorphisms and prostate cancer risk: A meta-analysis based on 38 independent studies","volume":"71","author":"Wang","year":"2011","journal-title":"Prostate"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdv545","article-title":"Does gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase iii trials","volume":"27","author":"Fizazi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.eururo.2015.10.021","article-title":"Prior endocrine therapy impact on abiraterone acetate clinical efficacy in metastatic castration-resistant prostate cancer: Post-hoc analysis of randomised phase 3 studies","volume":"69","author":"Bellmunt","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_32","first-page":"5615","article-title":"What predicts minimal response to abiraterone in metastatic castrate-resistant prostate cancer?","volume":"35","author":"Davies","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/HYPERTENSIONAHA.115.06925","article-title":"Common polymorphisms at the CYP17A1 locus associate with steroid phenotype: Support for blood pressure genome-wide association study signals at this locus","volume":"67","author":"Diver","year":"2016","journal-title":"Hypertension"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"E852","DOI":"10.1210\/jc.2011-2577","article-title":"Genetic polymorphism CYP17 rs2486758 and metabolic risk factors predict daily salivary 17\u03b2-estradiol concentration in healthy premenopausal norwegian women. The EBBA-I study","volume":"97","author":"Iversen","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/bjc.2015.128","article-title":"Circulating cell-free ar and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"112","author":"Salvi","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Agarwal, N., Alex, A.B., Farnham, J.M., Patel, S., Gill, D., Buckley, T.H., Stephenson, R.A., and Cannon-Albright, L. (2016). Inherited variants in sult1e1 and response to abiraterone acetate in men with metastatic castration refractory prostate cancer (mCRPC). J. Urol.","DOI":"10.1016\/j.juro.2016.04.079"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_38","first-page":"21","article-title":"Detection of AR-V7 mrna in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer","volume":"8","author":"Takeuchi","year":"2016","journal-title":"Res. Rep. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.mayocp.2011.09.009","article-title":"Germline predictors of androgen deprivation therapy response in advanced prostate cancer","volume":"87","author":"Kohli","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"16411","DOI":"10.18632\/oncotarget.3845","article-title":"Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer","volume":"6","author":"Xia","year":"2015","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eururo.2014.07.035","article-title":"Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer","volume":"67","author":"Huang","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/ng1669","article-title":"Efficiency and power in genetic association studies","volume":"37","author":"Yelensky","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/gepi.20533","article-title":"Mach: Using sequence and genotype data to estimate haplotypes and unobserved genotypes","volume":"34","author":"Li","year":"2010","journal-title":"Genet. Epidemiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"International HapMap Consortium (2003). The international hapmap project. Nature, 426, 789\u2013796.","DOI":"10.1038\/nature02168"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. B"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2105-11-134","article-title":"Probabel package for genome-wide association analysis of imputed data","volume":"11","author":"Aulchenko","year":"2010","journal-title":"BMC Bioinform."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/gepi.20310","article-title":"A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms","volume":"32","author":"Gao","year":"2008","journal-title":"Genet. Epidemiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/gepi.20430","article-title":"Avoiding the high bonferroni penalty in genome-wide association studies","volume":"34","author":"Gao","year":"2010","journal-title":"Genet. Epidemiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/gepi.20563","article-title":"Multiple testing corrections for imputed snps","volume":"35","author":"Gao","year":"2011","journal-title":"Genet. Epidemiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/7\/1097\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:25:46Z","timestamp":1760210746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/7\/1097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7]]}},"alternative-id":["ijms17071097"],"URL":"https:\/\/doi.org\/10.3390\/ijms17071097","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}